Preeclampsia is one of the most serious conditions at the end of pregnancy, causing increased perinatal morbidity and mortality to the pregnant mother and her product of conception. It remains a high-risk disease in ethnic minorities worldwide. Conception involves fetal invasion and implantation, followed by an actively forming and shedding decidua, an important uterine activity facilitating placental development. Dysregulation in conception mediates functional changes that induce onset of preeclampsia. The pathophysiology of preeclampsia primarily results from impaired trophoblastic invasion and implantation with subsequent vasculopathy. These events trigger exaggerated ischemic, inflammatory and immunologic events in the placenta bed that disrupt implantation. As the underlying mechanism(s) of preeclampsia remain obscure, there is increasing evidence that Vitamin D deficiency during pregnancy potentiates hypertensive states that could lead to the development of preeclampsia. As a prohormone, Vitamin D regulates molecular events within central pathophysiological pathways of implantation and vascular development. We review shared pathways involving Vitamin D modulation of pathologic events in implantation associated with preeclampsia. Understanding the causal mechanisms between Vitamin D and preeclampsia during early stages of conception could allude to development of candidate markers for treatment or screening, and decipher "hot spots" for research and intervention of, at-risk pregnant mothers.
Placental Invasion, Implantation and Vasculogenesis
The mammalian placenta is a vital organ of pregnancy, accepting the fetus as a semi-allogeneic product and functioning as the interface between maternal and fetal environments. This provides essential nutrients that regulate maternal-fetal hemodynamics. Normal pregnancy is associated with adaptive responses providing significant hemodynamic restructuring (physiologic) to ensure normal fetal growth. This restructuring process results in a decrease in total peripheral vascular resistance at the level of the placenta with an associated increase in maternal cardiac output, up to 30% to 45%, without elevations in systemic blood pressure [35] .
A. Normal implantation development ( Figure 1 ): It is well established that normal pregnancy progresses in a series of sequential chronological events represented by inflammation (implantation), anti-inflammation (gestation) and inflammation (parturition) [16] . Signals from maternal uterine endometrium allow the invasion of fetal trophoblasts into the uterine decidua during the process of implantation [36] [37] [38] . This requires that the mother recognize the newly developing embryo as immunological "self" in order to accept the fetal trophoblast [39] as an anergic, semi-allogeneic product. This becomes the initial role of the mother's innate immune system [40] .
Fetal cytotrophoblasts within the placenta differentiate into extravillous trophoblasts (EVT), which have an invasive phenotype [41] . A unique leukocyte subpopulation of maternal decidual Natural Killer (dNK) cells (uniquely identified as CD56 bright CD16 − ), key components of the innate immune system, are massively recruited at the site of embryonic implantation (decidua basalis) [7] . dNK cells function is determined by the balance between inhibitory and activating receptors. Expression of inhibitory killer-cell immunoglobulin-like receptors (KIR2DL4) on dNK cells, which are capable of recognizing and binding to both bioactive Vitamin D which mediates Th2 proliferation, clonal expansion, and anti-inflammatory cytokine production.
the classical HLA-class I and non-classical HLA-C and HLA-G receptors [42] expressed by and presented on fetal-EVT [40] , are necessary to establish the maternal-fetal interface. Ligand bound-KIR2DL4 receptor on dNK cells transduces signaling that confers inhibition of pathways which activate death effectors [43] .
This promotes immune tolerance by the dNK cells to the invading semi-allogeneic trophoblasts. This mechanism of dNK-mediated anergic trophoblast is critical to successful implantation [44] [45] enabling progressive anchoring and invasion into the maternal decidua. After acceptance by the maternal immune system, adequate spiral artery remodeling at the maternal-fetal interface [18] occurs, involving a highly choreographed cross-talk necessary for development of utero-placental perfusion [46] .
Perfusion enables flow of nutrients to the developing fetus. The adaptive immune system plays a role in activating placental cell expression of chemokines and cytokines in a redundant manner [47] and growth factors that together modulate the implantation process [48] . Thereafter, a series of cytokine influxes are involved in angiogenesis and vascular stability, in particular VEGF, PlGF and angiotensin II (Ang-II) [49] , leading to progressive placental perfusion [36] [50]
[51].
Implantation in preeclampsia ( Figure 2 ): Normal fetal EVT express increasing amounts of HLA-G with advancing invasive phenotype [45] . Genetic data have Open Journal of Obstetrics and Gynecology shown that mutations which inhibit proliferation, trafficking, or expansion of dNK cells [36] [52] or a combination of defects in expression of maternal KIR2DL4 and/or fetal HLA-G and HLA-C receptors [53] can challenge the mother's immunogenic tolerance for a successful implantation process, influencing the risk for preeclampsia [40] . Most preeclamptic placentae have absent or reduced HLA-G mRNA and protein expressions [36] 
Immune System in Placentation
Locally, decidualmonocytes, dendritic cells (DCs) and C CD4 + lymphocytes further modulate maternal immune tolerance, promoting myometrial invasion of trophoblast and subsequent vascular bed remodeling necessary for a successful implantation [23] [48].
Immune system in normal placental development: The maturation and activation of specific monocytes have various functions in implantation such as phagocytosis, antigen presentation and cytokine production. A state of induced immune tolerance of the mother for the fetus occur as: 1) DCs promote CD4 + helper 2 (Th2) dominance, therefore decreasing the Th1/Th2 ratio; 2) increased numbers of regulatory T cells (Tregs) which produce anti-inflammatory cytokines like Interleukin 10 (IL-10) help regulate the adaptive immune system's response to placental ischemia [23] ; and 3) an increase Treg/Th17 ratio which is favorable for immune tolerance [58] . This prevents vasoconstricting effects of endothelin-1 (ET-1) and reactive oxygen species (ROS) which are produced in response to ischemic conditions [23] [59]. Interestingly, interleukin 17 (IL-17) which is up regulated in many autoimmune disorders [23] is offset when this ratio is elevated.
Immune system in preeclampsia: The balance between Th1/Th2 is critical for healthy fetal implantation and pregnancy development. Th2 expressing cytokines (IL-4, IL-10 and TGF-β) are favorable for the maintenance of mammalian pregnancy [60] ; whereas, Th1 cytokines (IL-2, IFN-, TNF-α) are unfavorable since they are associated with rejection of the fetal allograft at the feto-maternal interface [61] . Placental ischemia in preeclampsia is associated with an immune imbalance where proinflammatory states are upregulated. There is a ratio bias between the two subpopulations of CD4 + T cells, Tregs and Th17s, where a reversal of the Treg/Th17 ratio prevail due to Th17 upregulation. This results in an uncontrolled proinflammatory environment which causes unfavorable immunogenic responses to the fetal allograft [62] . The anti-inflammatory cytokines of Tregs (IL-10 and Th2 cells) that help regulate healthy immune response loses their protective function, stimulation and proliferation during inflammation [23] . In addition, Th17 produces IL17, a proinflammatory cytokine. Both Th17 and neutrophil migration increase TNF-α and IL-6 in the myometrium, inducing massive inflammation that generate increased oxidative stress and ROS.
These effects are additive when producing endothelial damage/dysfunction; and as such, studies have shown that decrease in Treg populations is directly proportional to the severity of preeclampsia [63] . It has been shown that this cascade of events resemble inflammation similar to autoimmune diseases and other immunologic conditions that ultimately result in the maternal loss of immune tolerance for the fetus during pregnancy [64] . [17] . A reduction in the supply of oxygenated blood to the uteroplacental unit (Placental ischemia) not only causes a robust oxidative stress response but also stimulates hypoxia-factors which produce vaso-occlusive and/or vasoconstrictive substances, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) that contribute to the development of hypertension [23] . There is also decreased vasodilator nitric oxide (NO) and involvement of the adaptive immune pathway with B-cell production of autoantibodies that activate angiotensin II type I receptor (AT1).
Zenclussen et al. [61] showed a relationship between decidual expression of the Heme Oxygenase (HO) and NO in pregnant mice, along with a relationship to Th1/Th2 cytokine production. NO's vasodilatory role decreases systemic vascular resistance [67] . Previous observations suggested that regulation of the HO system is dependent on NO activity-both endothelial NO (eNO) and inducible NO (iNO) [68] . Purcell et al. described that increases in NO concentration during implantation could be necessary for developing adequate spiral artery structure within the myometrium and thus facilitating attachment [69] . Zenclussen et al. confirmed down-regulation of HO system in mice undergoing abortion accompanied by augmented Th1/Th2 cytokine ratio in a manner of pregnancy-incompatibility. This suggests that HO up-regulation is pregnancy-protective via decreasing the Th1/Th2 ratio or by protecting tissues from apoptosis [61] .
Furthermore, sEng induction by hypoxia, impairs binding of TGF-β to its receptors which leads to dysregulated TGF-β signaling in the vasculature; this mechanism was shown to inhibit formation of capillaries, in vitro, and induce vascular permeability and hypertension, in vivo [14] . Additionally, sEng has a downstream effect on e NOS activation and vasodilation [70] .
In summary, lack of vascular remodeling produces placental ischemia, which induces shallow trophoblast invasion and expansion that contributes to an in- . IL-10, produced by Tregs [78] in response to ischemia, can limit oxidative stress, and with the presence of calcitriol at the feto-maternal interface, modulates the immunological milieu to prevent rejection of the fetal allograft.
[48].
Smith et al. observed that deficiency in Vitamin D causes a cascade of changes in cytokine expression that closely mirrors the changes of inadequate trophoblastic invasion [76] . Proinflammatory cytokines are commonly elevated during preeclampsia [78] . yet the concentration of IL-10 was higher. By inhibiting the expression of peripheral blood TLR4 through Vitamin D3 supplementation, the incidence of preeclampsia lowered [78] . There is a link between CYP 27 B1 and immune function in the decidua which correlates with expression of TLR4 could indicate that Vitamin D may act in an autocrine/paracrine fashion in its regulation of both acquired and innateimmune responses [56] . Open Journal of Obstetrics and Gynecology [84] . Under physiologic conditions, these metabolic byproducts result in the following biological properties: antioxidants, vasodilatory, anti-thrombotic, anti-inflammatory, antiapoptotic and cytoprotective [85] [86] . The vasodilatory properties of heme catabolism is mediated mainly through endogenous carbon monoxide production that contributes significantly to the reduction of maternal peripheral vascular resistance and blood pressure [79] . Carbon monoxide can influence vascular tone independently [87] or influence other cytoprotective (anti-apoptotic, anti-inflammatory, antioxidant), vasoregulatory [88] or inhibitory effects in platelet aggregation pathways synergistic to NO [83] , further protecting vascular integrity. HO-1 expression is also induced by oxidative stress [89] to protect against vascular ischemia-reperfusion injury [46] during spontaneous vasoconstriction [90] ; and, its induction depends on gene transcription and protein synthesis [89] . The cellular protective function of HO-1, when expressed in endothelial cells, inhibits inflammatory responses which leads to graft acceptance [91] . HO-1 catabolizes heme to avoid toxic intracellular accumulation of free heme, preventing oxidative damage [92] .
HO-1 and preeclampsia: In humans, HO-1 polymorphisms have been associated with a spectrum of compromise to placental development [86] [93] including placental spiral artery remodeling [80] . cytokine (tumor necrosis factor-α) [94] . Studies have shown that HO-1-deficiency is associated with reduced stress defense and a proinflammatory tendency with susceptibility to vascular damage [10] . Stressed mammalian cells up regulate HO-1 during hypoxia-ischemia-reperfusion vascular injury as an adaptive mechanism to protect cells from oxidative damage. Its presence is a sensitive and reliable indicator of cellular oxidative stress. When oxidative stress occurs, high levels of oxygen free radicals are produced causing lipid peroxidation and endothelial lining damage [95] . The presence of cellular antioxidants, like HO-1, become crucial to reduce oxidative stress and prevent free radicle damage to blood vessels [10] . It is proposed that complications of pregnancy, such as recurrent miscarriages, intrauterine growth retardation and preeclampsia are associated with HO-1 deficiency [80] .
Vitamin D and HO-1 regulation: Hypoxia/oxidative stress, characteristic of placental trophoblastic dysfunction in preeclampsia, is also associated with imbalance between two cyclooxygenase metabolites, arachidonic acid thromboxane (TXA) and prostacyclin (PGI). A state of hypoxia/oxidative stress manifests increased TXA (a potent vasoconstrictor and facilitator of platelet aggregation) and a decreased prostacyclin production (a potent vasodilator) [96] . Experi- hypoxia/oxidative stress model resulted in a significantly reduced TXA and reduced ratio of TXA to PGI, suppressing hypoxia/oxidative stress. Although there was no effect on HO-1 upregulation, its effect on prostacyclin dominance could promote circulation and retard thrombosis in the placenta [95] . Although
Vitamin D has been shown to reduce oxidative stress by lowering the plasma oxidative stress marker and reducing inflammation during pregnancy-induced hypertension [97] , its direct role on HO-1 pathways remain to be clarified [98] .
Angiogenic Balance
Normal: The invasion of trophoblast into the placenta bed occurs as it adopts an endothelial phenotype with adhesion molecules for subsequent angiogenesis to evolve [2] . Preeclampsia and angiogenic imbalance ( Figure 3 ): Poorly developed blood supply through the placental vascular bed results in progressive placental hypoperfusion [101] and its resultant ischemia [7] . Lactate dehydrogenase (LDH) production has been used as an early clinical marker of anaerobic metabolism;
progressive LDH elevation reflects the severity of the hypoxic condition [27] .
The pathologic hallmark of preeclampsia is endothelial cell injury and dys- by reduced NO availability, which may stem from either decreased NO production or from increased NO inactivation [105] ; there is free radical damage causing detachment and apoptosis of endothelial cells [99] . Open Journal of Obstetrics and Gynecology During preeclampsia, there is a non-physiologic increase in syncytiotrophoblast apoptosis [104] [106] results in an increased syncytial debris (and knot formation) released into the maternal circulation [101] in an unscheduled manner. Candidate substances of excessive syncytial shedding into the maternal plasma during endothelial dysfunction act to provoke a maternal syndrome; they may serve to elevate antiangiogenic [107] substances. This pathophysiology is associated with upstream triggers of antiangiogenic promoters when angiogenic promoters [19] [108] are down regulated. The down regulation may involve other proangiogenic pathways, such as nitric oxide, heme oxygenase and hydrogen sulfide. Imbalances due to upregulated antiangiogenic promotors are evident when oxidative stress cause evolution of autoantibodies [2] .
The angiogenic imbalance favors the presence of several highly circulating antiangiogenic factors [109] of various sizes, shed from damaged placental endothelium [9] [46] , that can be detected as early as 11 -14 week of gestation [110] prior to the onset of preeclampsia. The circulating antiangiogenic factors which have been used as predictive biomarkers of preeclampsia are: high levels of sFlt-1, sEng [14] [19] and tissue transglutaminase (tTG) [12] and decreased circulating levels of free vascular endothelial growth factor (VEGF) [12] [14] . There are other circulating levels of cellular microparticles that are elevated during preeclampsia [14] [38] [46] .
Angiogenic pathways allow free VEGF to bind to PlGF activating VEGF receptor type 2 (VEGFR 2) that supports vascular growth. SFlt-1, a unique receptor for VEGF, is produced primarily by the syncytiotrophoblast syncytial knots Open Journal of Obstetrics and Gynecology of the placenta [111] . Although the placenta produces sFlt-1 during normal pregnancy, higher amounts of sFlt-1 are produced from the hypoxic preeclamptic placentae [112] . Elevated sFlt-1 binds to free VEGF and PlGF in the maternal circulation, reducing each's binding affinity for their membrane receptor [113] , there by inhibiting the effects of VEGF binding to PlGF on maternal endothelial cells and podocytes [114] . This reduces endothelial integrity and function [113] as well as placenta vascular growth [80] . Findings suggest that concentrations of sFlt-1 increases steeply about five weeks before the onset of clinical preeclampsia compared to controls; although, sFlt-1 normally increase in late gestation [113] .
The relationship of sFlt-1 to angiogenic PlGF has been clinically studied in ethnic population with preeclampsia. African-American women with preeclampsia (means gestational age of 32.3 weeks and with high BMI) were found to have significantly lower levels of PlGF (90.3 ± 8.9 pg/ml versus 172.8 ± 20.2 pg/ml; p < 0.01), higher sFlt-1 (2087.3 ± 200.1 pg/ml versus 1546.5 ± 91.9 pg/ml; p < 0.01) and a higher sFlt-1/PLGF ratio (66.8 ± 18.7 versus 22.3 ± 2.9; p < 0.01) compared to racially-matched normotensive controls [108] . This increase sFlt-1/P1GF ratio paralleled a decrease in the free VEGF and free PlGF levels, suggesting a decrease in these angiogenic factors attributed to binding by sFlt-1.
Low concentrations of PlGF during early gestation have been associated with greater risk of early-onset preeclampsia. Although low PlGF has not been shown to be a predictive marker for onset of preeclampsia at ≥37 weeks [113] , it has high sensitivity and negative predictive value for preeclampsia manifesting within 14 days of preeclamptic symptoms before 35 weeks' gestation [115] .
Therefore, using PlGF-based tests for patients with suspected preeclampsia at 20 -37 weeks could provide diagnostic accuracy and cost-effectiveness [116] . Other studies have shown that circulating antiangiogenic factor have played major roles for predicting the severity of preeclampsia, either alone or in combination, with other clinical parameters and chemical markers [12] [70] [110] [114] [117] early in gestation. It also has the potential to predict restricted fetal growth in advanced gestation [14] [118]. autoantibodies that act directly on AT1 [125] . It is associated with suppression of both circulating renin and aldosterone levels. This disturbs the RAAS regulation via aldosterone during normal pregnancy, which provides a delicate balance by increasing intravascular volume at no expense to cardiac output [35] .
Vitamin D and Vasculogenesis
AT1-AA are associated with increased angiotensin II (ANG-II) sensitivity during PE with a tendency to increase blood pressure at lower ANG-II stimulation [126] with vascular smooth muscle constriction [7] . These antibodies can be associated with greater severity of disease when present at midgestation [7] . The production of AT1-AA has been shown to mediate a path towards chronic inflammation [24] . Although AT1-AA may occur early, at the initial time of placental hypoxemia, its utility as a sensitive biomarkers to predict progression of preeclampsia needs more clarity [124] .
Vitamin D: There are studies that argue a beneficial role of Vitamin D on various hypertensive disorders of pregnancy related to AT1-AA. Studies investigating double-transgenic rats with excess Ang-II production fed Vitamin D-depleted (experimental group) chow for 3 weeks (short-term) showed higher mean systolic BP and upregulated angiotensin metabolites, including Ang-II, and its counter-regulatory breakdown product. This aggravated hypertension lead to target-organ damage [114] . They concluded that even a short-term severe Vitamin D deficiency may directly promote hypertension and impact the RAAS system that could contribute to target-organ damage [127] . Another study revealed that after 8-weeks of cholecalciferol therapy in hypertensive patients with hypovitaminosis D, there was a significant reduction in circulating renin-angiotensin-aldosterone and improved vascular function compared to controls [128] . Recently, it was confirmed that AT1-AA associated preeclampsia was 
Candidate Hot Spots
Pregnancy presents a challenging period when Vitamin D availability becomes essential to utero-placental sufficiency [130] [131], especially to deter early-onset pathophysiologic events of preeclampsia [132] . Clinically, Vitamin D sufficiency [139] and ethnically related low affinity for VDBP [139] . Additionally, production and secretion of 1, 25 (OH) 2D 3 during pregnancy by both the kidneys and placenta play a role in availability [140] ; 2) polymorphism within kinetic and dynamic pathways of molecular activation [137] [138] and transport [141] ; We recommend research to establish diagnostic toolkit to detect these high-risk pregnancies during early gestation. This should involve standardized measurement of Vitamin D levels by Mass Spectrometry (the gold standard).
Genotyping VDBP and its common pathway allele variant to establish "bioavai- 
Conclusions
From our review, we have demonstrated numerous causal relationships between preeclampsia and Vitamin D. As we tracked the events from inception of implantation (time of fetal EVT invasion) up to the third trimester of pregnancy, Vitamin D deficiency has remained a single nutritional condition that shares most of the adverse pathophysiology of preeclampsia ( Table 1) . The "Molecular Concept of Low Vitamin D" has been shown to potentiate preeclampsia through numerous and common pathways via both intracrine and/or paracrine mechanism(s). Many studies have used Vitamin D to reverse molecular and pathophysiologic changes of preeclampsia to a major extend. Research publications have documented that Vitamin D supplementation can promote a healthy pregnancy from inception, and prevent early insidious events leading to preeclampsia. 
